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Throughout the life cycle the skeleton requires optimum development and maintenance of its
integrity to prevent fracture. Bones break because the loads placed on them exceed the ability
of the bone to absorb the energy involved. It is now estimated that one in three women and one
in twelve men aged >55 years will suffer from osteoporosis in their lifetime and at a cost in the
UK of >£1.7 · 109 per year. The pathogenesis of osteoporosis is multifactorial. Both the
development of peak bone mass and the rate of bone loss are determined by key endogenous
and exogenous factors. Ca supplements appear to be effective in reducing bone loss in women
late post menopause (>5 years post menopause), particularly in those with low habitual Ca
intake (<400 mg/d). In women early post menopause (<5 years post menopause) who are not
vitamin D deficient, Ca supplementation has little effect on bone mineral density. However,
supplementation with vitamin D and Ca has been shown to reduce fracture rates in the insti-
tutionalised elderly, but there remains controversy as to whether supplementation is effective in
reducing fracture in free-living populations. Re-defining vitamin D requirements in the UK is
needed since there is evidence of extensive hypovitaminosis D in the UK. Low vitamin D
status is associated with an increased risk of falling and a variety of other health outcomes and
is an area that requires urgent attention. The role of other micronutrients on bone remains to be
fully defined, although there are promising data in the literature for a clear link between
vitamin K nutrition and skeletal integrity, including fracture reduction.
Osteoporosis: Fracture: Vitamin D: Calcium: Vitamin K
Bones break because the loads placed on them exceed their
ability to absorb the energy involved(1). This outcome is
likely to be the result of a number of factors including, but
not limited to: a reduction in bone mass; a change in the
distribution of bone; loss of cancellous or cortical micro-
architecture; an accumulation of damaged bone; a change
in the material properties of the remaining bone(2).
Bone is a living tissue. There is a continuous cycle of
active bone formation (through the activity of osteocytes
and osteoblasts) and bone resorption (involving osteo-
clasts). Fig. 1 shows the sequence of events in the bone
remodelling sequence. Osteoclasts are attracted to a
quiescent bone surface and then excavate an erosion
cavity. Mononuclear cells smooth off the erosion cavity,
which is a subsequent site for the attraction of osteoblasts
that synthesise an osteoid matrix. Continuous new bone
matrix synthesis is followed by calcification of the newly-
formed bone. When complete, lining cells once more
overlie the trabecular surface(3).
Osteoporosis is defined as a metabolic bone disease
‘characterised by low bone mass and microarchitectural
deterioration of bone tissue, leading to enhanced bone
fragility and a consequent increase in fracture risk’(4,5).
There is a normal mineral:collagen, unlike that of other
metabolic bone diseases such as osteomalacia (which
is characterised by deficiencies of mineral relative to
collagen)(6). An example of osteoporotic and normal bone
is shown in Fig. 2.
Abbreviations: BMD, bone mineral density; 25 OHD, 25-hydroxyvitamin D.
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Public health impact of poor bone health
Globally, it is estimated that one in three women and one
in twelve men aged >50 years will suffer from osteo-
porosis in their lifetime, which roughly equates to three
million individuals(7). There are >230 000 osteoporotic
fractures occurring every year in the UK at a cost of
>£1.7 · 109 per year. In Europe the cost of treating
osteoporotic fractures is an important contributor to the
financial implications of osteoporosis generally (it is esti-
mated that E13.9 · 109 is the expected annual total cost
relating to osteoporosis)(8). Specifically, hip fractures
Normal bone Osteoporotic bone
Fig. 2. Examples of normal and osteoporotic bone under the microscope. (From Eastell(3); reproduced
with permission.)
(A) (B) (C) (D)
(E) (F) (G) (H)
Fig. 1. Steps in the remodelling sequence of cancellous bone. Osteoclasts are attracted to a quiescent bone surface (A) and then
excavate an erosion cavity (B, C). Mononuclear cells smooth off the erosion cavity (D), which is a subsequent site for the attraction of
osteoblasts that synthesise an osteoid matrix (E). Continuous new bone matrix synthesis (F) is followed by calcification (G) of the newly-
formed bone. When complete, lining cells once more overlie the trabecular surface (H). (From the National Osteoporosis Society(14);
reproduced with permission.)
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account for more than one-third of the total cost of osteo-
porosis and are a reflection of the inpatient (hospital) and
outpatient (nursing home) care(9). Furthermore, the WHO
has projected a rise in osteoporotic fractures from
1.66 · 106 hip fractures in 1990 to 6.26 · 106 in the 2050,
which suggests that the future economic impact of osteo-
porosis will be enormous(10).
Changes in bone mass with ageing
Considerable changes in skeletal mass occur during the life
cycle. Adult bone health is predominantly determined by
three key factors: the maximum attainment of peak bone
mass, which is achieved during growth and early adulthood;
maintaining bone mass in adulthood; reducing the rate of
bone loss with advancing age, with the menopausal years
being a time of considerable concern for women (Fig. 3)(11).
Both peak bone mass attainment in the younger population
and the rate of bone loss in post-menopausal women and
the elderly are determined by key endogenous and exo-
genous factors, i.e. a combination of genetic, endocrine,
mechanical and nutritional factors(12), with evidence of
extensive interactions within and between these groups.
Calcium nutrition: important concepts
Ca is the most abundant mineral in the body(13). Approxi-
mately 1.2 kg (equivalent to about 300 mmol) is contained
within the human body, with 99% of this Ca being located
within the bones and teeth. Ca is also located in body fluids
and soft tissues. It has two key roles: (1) supporting
structural integrity; (2) regulating metabolic function(14).
Ca is essential for: cellular structure; intercellular and
intracellular metabolic function; signal transmission;
muscle contractions, including heart muscle; nerve func-
tion; activities of enzymes; normal clotting of blood. There
is no functional marker of Ca status, since its role in
normal blood clotting takes priority and hence plasma Ca
is maintained within very narrow limits (Fig. 4)(15).
Ca metabolism
Ca absorption occurs predominantly in the jejunum and
also in the ileum and colon. Uptake occurs by active
transport and simple passive diffusion. At low Ca intakes
active transport predominates, but as intakes increase more
is absorbed by non-specific pathways(16). The metabolite of
vitamin D (1,25-dihydroxycholecalciferol) stimulates Ca
transport across the intestinal cells by inducing the pro-
duction of a Ca-binding protein. This process occurs within
the villus cells through the normal process of receptor
binding, DNA interaction and messenger RNA production.
Hence, vitamin D is critical for effective Ca absorption(17).
Ca is lost mainly through renal excretion but there are
data to also support losses occurring via faeces, sweat, skin
and hair, as well as nails. Ca enters the gut via the bile,
which is known to be relatively rich in Ca. It also enters
the gut in pancreatic secretions and as part of desquamated
cells from the mucosal lining. It may also be reabsorbed
from the ileum and colon. As a result of the endogenous
secretion the net absorption is less than gross dietary
absorption by approximately 100 mg. Plasma Ca is tightly
maintained at a level of 90–105 mg/l, of which approxi-
mately 50% is ionised. The plasma ionised Ca compart-
ment is maintained by a combination of humeral factors
that regulate intestinal absorption, renal loss and deposition
or mobilisation of Ca from bone(18).
Urinary Ca excretion
Approximately 97% of the filtered Ca load is re-absorbed
by the renal tubules and the remaining 3%, which is
Bo
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Fig. 3. Changes in bone mass during the life cycle. Critical times are: (1) attainment of peak
bone mass (PBM; 0–28 years of age, with pubertal years being particularly crucial); (2) meno-
pause ( ; during the menopause and £ 10 years post menopause it is estimated that 1–2% of
bone is lost per year); (3) age-related bone loss (a low bone mineral density threshold increases
osteoporosis fracture risk).
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excreted in urine, represents the obligatory loss. The major
determinant of urinary Ca excretion is dietary Ca intake.
Urinary Ca excretion is higher when protein and Na
intakes are high than when intakes of these two nutrients
are low. The effects of a high protein intake on Ca excre-
tion may be partly offset by higher P intake. Urinary Ca
excretion decreases in old age with glomerular filtration
rate. Also, intestinal absorption declines as the result of a
reduction in the efficiency of parathyroid hormone and
vitamin D metabolism. Increased urinary Ca in women at
the menopause reflects the increased mobilisation of bone
Ca because of oestrogen deficiency(19).
Control of Ca balance
An adult on a normal mixed diet is usually in a state of
equilibrium, i.e. the amount lost in the faeces and urine is
approximately equal to the amount present in the food. In
growing children the body is normally in positive balance.
Ca is steadily maintained for the formation of new bone.
When the need of the bones is great the net absorption of
dietary Ca via the intestinal mucosa can be much greater
than normal. The main features of Ca balance include a
miscible pool mainly in blood and extracellular fluids,
which provides for the slow turnover in bones. The pool is
replenished by dietary Ca and losses occur in urine.
It is very important to note that the concentration of
plasma Ca is finely regulated and controls the size of the
pool. Ca balance is hence actively controlled by a large
number of factors. The external balance of Ca (the differ-
ence between intake and output) is, in effect, determined
by the exchange between the skeleton, the intestine and
the kidney. These fluxes are controlled by the action
of calciotrophic hormones: parathyroid hormone; 1,25-
dihydroxycholecalciferol; calcitonin. It is also influenced
by other factors such as sex hormones, growth hormones,
corticosteroids and a variety of locally-acting hormones
(Fig. 4)(20).
Within bone, Ca is in the form of hydroxyapatite
crystals (Ca10 (PO4)6 (OH)2), which also contain P and Mg,
and contributes to its strength. P is found in abundance in a
variety of foods but Mg is more limited and is an area of
bone health nutrition that requires further attention.
Calcium and peak bone mass development
Peak bone mass is one of the key factors determining bone
mass and fracture risk later in life. Attaining a high peak
bone mass within an individual’s genetic potential is a
key preventative strategy for fracture reduction. Hence,
the focus of research must be more fully directed on
modifiable factors affecting the peak attainment of bone. It
is known that genetic factors do play a key role in the
variation of peak bone mass, with estimates of approxi-
mately 70–75%(21), which still leaves plenty of room for
key exogenous factors such as diet and physical activity to
play a key role in bone mass development.
The length of time peak mass is maintained before age-
related bone loss begins is approximately 28 years of age.
There are some studies that indicate that the duration is
relatively brief and others that indicate it may last several
years. This disparity appears to depend on the skeletal
region examined(22), and is likely to become clearer as
more longitudinal studies are published. There are data,
however, to show that both Ca absorption and bone Ca
Active absorbtion
1,25 (OH)2D3
Dietary Ca
Small intestine
Large intestine
Parathyroid
hormone
1,25 (OH)2D3
Urinary Ca
Calcitonin
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Calcitonin
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Vitamin D
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Total: 90–110 mg/l
Protein bound: 36–44 mg/l
Ligand bound: 6–12 mg/l
Ca   ions: 44–52 mg/l
Fig. 4. Regulation of calcium levels in blood and tissue. 1,25 (OH)2D3, 1,25-dihydroxycholecalciferol. (From
Smith(12); reproduced with permission.)
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deposition rates peak in girls shortly before menarche(23),
which raises key questions as to the most effective timing
of Ca and physical activity strategies for improving peak
bone mass attainment.
Low Ca intakes during growth and late menarcheal age
will affect peak bone mass, and consequently are likely to
impact on fracture risk later in life. There are some studies
that indicate that adolescent girls are less likely than boys
to meet the current recommended dietary levels for Ca
(although under-reporting may be a key confounding factor
in these studies)(24).
Clinical trials with Ca supplements in both children and
teenagers have shown an overall positive effect of Ca on
bone mass accrual. The effect has been shown to be
between 1 and 6% per year in the total body and between 1
and 10% per year at different specific skeletal regions
when compared with a placebo(25). However, the studies
have only been of short duration (between 1 and 3 years).
Pubertal stage is critical in relation to the effectiveness of
the supplement. For example, a study of adolescent girls
post menarche (<15.5 years of age) who had baseline low
Ca intakes (<800 mg/d) has shown enhanced bone mineral
acquisition in those girls given a 1000 mg/d supplement in
comparison with girls given a placebo(26). The effect was
observed to be especially evident in girls who were >2
years past the onset of menarche.
In a follow-up study to a 3.5-year Ca supplementation
trial in ninety-six adolescent girls multivariate analysis has
revealed that total-body bone mineral density (BMD)
accrual over the 7 years (original and follow-up study) in
the active-treatment cohort is attributable to Ca supple-
mentation(27). A further 8-year follow-up study of Ca sup-
plementation in girls who were prepubertal has suggested
that prepubertal Ca intake may also have an effect on the
timing of menarche(28). The areal BMD gain between 7.9
and 16.4 years of age was found to be inversely related to
menarcheal age at the axial and appendicular skeletal sites.
A significant difference was observed between groups in
relation to menarcheal age, with girls in the Ca-supple-
mented group starting menarche approximately 5 months
sooner. On subgroup analysis based on menarcheal age it
was found that the mean areal BMD gain from baseline in
girls whose menarcheal age was below the median (13
years) remained significantly greater at all sites measured.
In the late-menarche subgroup no lasting effect of Ca
supplementation on BMD was observed. The authors
suggest that Ca supplementation in prepubertal girls may
accelerate the onset of pubertal maturation.
These data indicate the importance of Ca to peak bone
mass development, although further research is clearly
required to identify the exact mechanisms of an effect of
increased Ca on pubertal timing(29).
Calcium and physical activity interactions: effects on
peak bone mass attainment
Over 100 years ago, the German scientist Julius Wolff
proposed the theory that is known as ‘Wolff’s Law’: ‘bone
accommodates the forces applied to it by altering its
amount and distribution of mass’(30). More recently, this
concept has been refined to a general theory of bone mass
regulation, known as the mechanostat model(31). It is well
known that in the absence of weight-bearing exercise bone
loss will occur at both axial and appendicular skeletal sites.
A 3-year longitudinal investigation has shown consistently
higher bone mineral content in young girls regularly
undertaking weight-bearing exercise in comparison with
healthy controls, despite late age of menarche or amenor-
rhoea (Fig. 5)(32). Controlled intervention studies provide
stronger evidence that effects of activity are causal and can
be attained in less-active children who start to exercise
(Fig. 6(33)). Several such studies have examined the effects
of exercise interventions on bone in children, with BMD or
bone mineral content gains in the order of 1–5% greater in
the exercise-intervention group than in the control
groups(33,34). Structural adaptation also seems to occur,
including increases in bone area, bone circumference and
bone width.
There are increasing data to suggest that both Ca and
physical activity work synergistically on the skeleton(35). A
randomised controlled trial in young children (3–5 years)
has shown that exercise increases leg bone mineral content
in children receiving a Ca supplement (1000 mg/d) but not
in those receiving a placebo(36). Cortical thickness and area of
the tibia have also been found to increase in response to
activity in children taking Ca, but to decline in those
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Fig. 5. Positive effect of impact loading exercise on peak bone
mass attainment in young female gymnasts (n) in comparison with
healthy controls (CON; *) based on total-bone (TB) bone mineral
content (BMC) by maturity (biological age 0 being the age of puberty
and peak height velocity). Values are means with their standard
errors represented by vertical bars. When adjusted for height and
weight mean values were significantly different from those for CON:
**P<0.01, *** P<0.001. (From Nurmi–Lawton et al.(32); reproduced
with permission.)
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receiving a placebo. Similar results have also been reported
for older children (7–11 years); greater leg bone mineral
accrual was found with a combination of a Ca supplement
(800 mg/d) and exercise compared with either treatment
alone(37). Hence, adequate Ca intake may be essential for
optimal skeletal response to exercise and exercise might
enhance effects of Ca at weight-bearing sites(38).
Calcium and post-menopausal bone loss
There are now good data to show that Ca supplements are
effective in reducing bone loss in women late post meno-
pause (>5 years post menopause), particularly in those
with low habitual Ca intake (<400 mg/d)(39). A key study
has shown that women late post menopause have a sig-
nificant reduction in lumbar spine and femoral neck bone
loss following supplementation with 500 mg Ca/d, with no
such effect in women early post menopause (<5 years post
menopause)(40) (Table 1). A review of over twenty studies
has shown that Ca supplementation can decrease bone loss
by approximately 1% per year(41) and a meta-analysis
that included fifteen trials indicates that Ca supplemen-
tation at levels between 500 and 2000 mg/d reduces post-
menopausal bone loss(42); Ca changes were of the order of
1.66% at the lumbar spine and 1.64% at the hip. There are
some data to suggest that the effect of Ca supplementation
may be greater at skeletal sites with more cortical
bone(43,44). There are also data to suggest that Ca supple-
mentation improves the efficacy of antiresorptive therapy
on bone mass(45).
Vitamin D nutrition: key concepts
Types of vitamin D
Vitamin D is the generic term for two molecules, i.e.
ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3).
Ergocalciferol is derived by UV irradiation of ergosterol,
which is found in fungi and plants(46). Cholecalciferol is
formed from the effect of UV irradiation on the skin and
the efficiency of cholecalciferol synthesis is dependent on
the number of UVB photons that penetrate into the epi-
dermis. As shown in Fig. 7, the action of sunlight on the
skin converts 7-dehydrocholesterol to previtamin D, which
is metabolised to vitamin D by a temperature-dependent
isomerisation. Vitamin D is then transported via the
general circulation to the liver, where the enzyme 25-
hydroxylase converts it to 25-hydroxycholecalciferol (25
OHD). The kidney is the site for further conversion to
1,25-dihydroxycholecalciferol. 25 OHD is the best indi-
cator of clinical status and is the key circulating vitamin D
metabolite(47). 1,25-Dihydroxycholecalciferol is the active
form of the vitamin, which is involved in Ca homeostasis,
helping to maintain normal blood levels of Ca and P and
promoting Ca absorption and bone mineralisation(48).
Sources of vitamin D
It is believed that the main source of vitamin D is the UV
in sunlight. However, whether UV exposure is sufficient
Fig. 6. An example of a jumping programme that improves hip and
lumbar spine bone mass in prepubescent children. (From Fuchs
et al.(33); reproduced with permission.)
Table 1. Calcium supplementation and post-menopausal bone loss
in healthy women who received placebo or either calcium citrate
malate (CCM) or calcium carbonate (CC; 500 mg calcium/d) for 2
years (from Dawson-Hughes et al.(40); reproduced with permission)
Treatment
groups
Percentage change in lumbar spine BMD
After 1 year After 2 years
Mean SE Mean SE
CCM 0.60 0.56 0.41 0.69
CC 0.28 0.56 - 0.07 0.69
Placebo - 0.72 0.49 - 1.33 0.60
BMD, bone mineral density.
7-Dehydrocholesterol
UVB
Cholecalciferol
Liver
Kidney
25(OH)D3
many tissues
Calcitroic acid
1,24,25(OH)3D3
1,25(OH)2D3
OHHO
CH2
CH3
19
6
7
21 22
20 23 25
2624
OH
27
8
12
9 14
13 1716
15
11
2
5
3 1
104
24,25(OH)2D3
Fig. 7. Metabolism of vitamin D. 25(OH)D3, 25-hydroxy-
cholecalciferol; 1,25(OH)2D3, 1,25-dihydroxycholcalciferol; 24,25
(OH)2D3, 24,25-dihydroxycholcalciferol; 1,24,25(OH)3D3, 1,24,25-
trihydroxycholcalciferol. (From Holick(54); reproduced with permis-
sion.)
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to keep vitamin D levels optimal has recently been the
subject of considerable debate(49), particularly given the
evidence of extensive hypovitaminosis D in the UK.
Findings of the National Diet and Nutrition Surveys (4–18
years(50), 19–64 years(51) and ‡ 65 years(52)) indicate that
vitamin D ‘deficiency’ (defined as a plasma 25 OHD level
<25 nmol/l or 10 ng/ml) is a problem (e.g. 24% of men
and 28% of women in the age-group 19–24 years have
levels <25 nmol/l(51)). More recently, data from the 1958
British birth cohort (n 7437) has shown extensive hypo-
vitaminosis D in subjects at 45 years of age; 25 OHD
levels <25, <40 and <75 nmol/l were found in 15.5, 46.6
and 87.1% of the population respectively, with lower
levels in the north v. south(53) (Fig. 8).
Much of the UV in sunlight is absorbed by clouds, O3
and other forms of atmospheric pollution. With a reduced
zenith angle of the sun and increased path length of sun-
light through the atmosphere, the effective level of
UV energy decreases north–south with distance from the
seasonally-varying latitude at which the sun is directly
overhead(54). Hence, in areas of northern latitude (such as
the UK) there is no UV radiation of the appropriate
wavelength (280 mm–310 mm) from the end of October to
the end of March. For the remaining months of the year the
main percentage of the effective UV radiation occurs
between 11.00 hours and 15.00 hours(55).
A number of factors affect vitamin D production from
UV exposure: (1) sunscreens absorb UVB radiation when
applied to the skin; hence, there is marked reduction in the
penetration of UVB photons into the epidermis and as a
result production of pre-cholecalciferol is markedly
reduced; (2) glass absorbs all UVB photons and hence
exposure of the skin from sunlight that has passed through
glass will not promote cholecalciferol synthesis in the skin;
(3) clothing also absorbs UVB radiation and so no chole-
calciferol is made in the skin covered by clothing; hence,
women who cover up for cultural reasons are vitamin D
deficient and this factor represents an area of research that
requires urgent attention.
As shown in Table 2, there are few dietary sources of
vitamin D. The major providers are fat spreads (which
are fortified with vitamin D), fish, eggs, pastry products,
fortified breakfast cereals and meat(56). Recent changes in EU
regulations have resulted in a number of cereal manu-
facturers removing the vitamin D fortification(57). Key
Food Standards Agency-funded research on the interaction
between diet and sunlight exposure on vitamin D status is
currently underway and results will provide core inform-
ation on vitamin D requirements(58).
Importance of vitamin D to bone
Vitamin D stimulates bone matrix formation and bone
maturation. It also enhances osteoclastic activity and there
are some data to suggest that it may influence different-
iation of bone cell precursors(59). Together with para-
thyroid hormone, it regulates Ca and P metabolism and
promotes Ca absorption from the gut and kidney
tubules(60). It has been shown that fractional Ca absorption
increases with serum 25 OHD concentrations within the
reference range, up to a level of 80 nmol/l, reaching a
plateau above that level(61).
Vitamin D and peak bone mass development
There is growing evidence that mild vitamin D insuffi-
ciency can have a detrimental effect on bone mineral mass
in adolescent females(62) and children(63,64). A 3-year pro-
spective cohort study in 171 healthy Finnish girls aged
9–15 years comparing subjects with severe hypovit-
aminosis D (25 OHD <20 nmol/l) with those with normal
vitamin D status (25 OHD ‡37.5 nmol/l) has found a dif-
ference of 4% in BMD accrual(64). The adjusted change in
Winter Spring Summer Fall
Fig. 8. Evidence of extensive hypovitaminosis D in the UK from the 1958 British Cohort (n 7437).
25-hydroxyvitamin D levels (nmol/l) of <25 (10 ng/ml), <40 (16 ng/ml) and <75 (30 ng/ml) were found in
15.5, 46.6 and 87.1% of the population respectively. Distribution in the population: (K), 5–9.9%; ( ),
10–19.9%; ( ), 20–29.9%; ( ), 30–39.9%; ( ), 40–49.9%; ( ), 50–59.9%; (&), 60–69.9%. (From
Hyponnen & Powers(53); reproduced with permission.)
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lumbar spine BMD was shown to be 27% higher for sub-
jects in the highest tertile of vitamin D intake compared
with those in the lowest tertile. Interestingly, the findings
were reported to be significant only for girls at the post-
pubertal stage, with no differences for girls of less maturity
(<12 years); a finding that has been reported previously(65).
Low vitamin D status is a risk factor for attaining a
reduced peak bone mass(66).
In a key vitamin D-supplementation study on bone
mineral accretion in 212 adolescent girls who were Ca
replete (mean age 11.4 years) bone mineral augmentation
at the femur was found to be 14.3 and 17.2% higher in the
groups receiving the vitamin D supplementation (at either
5mg/d or 10mg/d) in comparison with the placebo
group(67). The findings followed a dose–response relation-
ship for those subjects who were Ca replete. A difference
was also seen for lumbar spine bone density between the
group supplemented at 10mg/d level and the placebo
group. Furthermore, vitamin D supplementation was found
to significantly reduce bone resorption (as assessed by
urinary deoxypyridinoline excretion). These findings were
only observed to be significant when the data were ana-
lysed by the compliance-based method (which includes
only participants who complied with instructions) as
opposed to the intention-to-treat method (which includes
all participants who entered the trial). Further research is
required on the combined effect of Ca and vitamin D on
maximising peak bone mass attainment, particularly in
children accustomed to a low Ca intake.
Calcium and vitamin D in fracture prevention
Ca and vitamin D supplementation studies have been
shown to reduce fracture rates in institutionalised elderly
individuals(68). Women living in nursing homes in France
were given a 1200 mg Ca supplement and 20mg vitamin D
daily for a period of 18 months. Both hip fracture
(P = 0.040) and non-vertebral fractures (P = 0.015) were
shown to be significantly reduced in those women on the
active treatment in comparison with the placebo (Fig. 9).
There are also data to suggest an effect of Ca and
vitamin D on fracture prevention in free-living elderly
populations. Elderly American men and women (mean age
71 years) given 500 mg Ca and 20mg cholecalciferol daily
were found to have a reduced total number of non-
vertebral fractures(69). In a factorial cluster-randomised
pragmatic intervention study of 9605 community-dwelling
residents living in a northern European region (Denmark) a
daily supplement of CaCO3 (1000 mg) and vitamin D
(10mg) over a period of 3 years was reported to result
in a 16% reduction in fracture incidence rate (relative
risk 0.84 (95% CI 0.72, 0.98) in treated subjects compared
with those subjects who were offered no supplement but
participated in an environmental and health programme(70).
Vitamin D supplementation alone is not effective
in preventing fractures in the elderly if the dosage is
limited. For example, a supplementation trial undertaken in
Norway using cod liver oil that provided 10mg vitamin D/d
was not found to prevent osteoporotic fractures in 1144
nursing home residents(71). It is important to note that a
recent meta-analysis indicates that 17.5–20mg/d reduces
the risk of hip and any non-vertebral fractures in ambu-
latory or institutionalised elderly individuals, but 10mg/d is
not effective(72).
A recently published study examining the effect of three
injections of 7500mg cholecalciferol per year has found no
reduction in fracture risk in 9000 healthy ambulatory
elderly men and women and, if anything, has shown that
the vitamin D supplementation increased the risk of frac-
ture (P<0.06)(73). This finding contrasts with the results of
a study of elderly British men and women aged 65–85
years in which it was shown that supplementation with
2500mg cholecalciferol orally every fourth month for 5
years reduces the number of fractures of the hip, wrist,
forearm and spine by 22% compared with placebo(74).
Two key UK studies have not demonstrated a positive
effect of Ca and vitamin D supplementation on fracture
prevention in the free-living elderly population(75,76).
In a pragmatic open randomised trial conducted with
3314 women aged ‡ 70 years who had risk factors for
hip fracture Ca (1000 mg/d) and cholecalciferol (20mg/d)
Table 2. Vitamin D content of foods* (from Lanham-New et al.(56);
reproduced with permission)
Food
Vitamin D
content
(mg) per
portion‡
Cod liver oil (one tablespoon; 11 g) 23
Salmon steak, steamed (100 g) 8.7
Sardines, tinned in tomato sauce (100 g) 8.0
Tuna, tinned in brine (100 g) 3.6
Mackerel, one small, smoked (100 g) 8.0
Herring, one small fillet, grilled (85 g) 13.7
Pilchards, tinned in tomato sauce,
small tin (50 g)
7.0
Minced beef, small portion, stewed (100 g) 0.8
Beef rump steak, grilled, (102 g) 0.4
Lamb, leg, roast (90 g) 0.6
Pork chop, grilled (120 g) 1.0
Liver (all types), stewed or fried (50 g) 0.15–1.1
Egg, one medium, boiled (61 g) 1.1
Fortified products
Margarine, polyunsaturated, spread on two
slices of bread (14 g)
1.1
Breakfast cereals fortified with vitamin D (30 g)† 0.6–2.5
Two types of fromage frais currently on the
market fortified with vitamin D (100 g)†
0.9–1.3
A few types of yogurts currently on the market
fortified with vitamin D (100 g)†
0.84–1.16
Two types of yogurt drinks currently on the
market (90 g)†
0.7–1.1
Processed cheese ‘triangle’ fortified with vitamin D
(approximately 22.5 g)†
1.0
Processed cheese slice fortified with vitamin D
(approximately 25 g)†
0.9
Processed cheese strip fortified with vitamin D
(approximately 21 g)†
0.9
*Portions are for adolescent boys and girls and adults and portions sizes (with
the exception of items indicated) are from Food Standards Agency(94).
†Portion size and values taken from packaging information.
‡Values (with the exception of items indicated) are from McCance &
Widdowson(95).
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supplementation was not found to reduce the risk of frac-
ture(75). No evidence of an effect on falls at either 6
months (OR 0.99 (95% CI 0.81, 1.20) or 1 year (OR 0.98
(95% CI 0.79, 1.20)) were seen. Adherence rate (60%),
however, was low. In the MRC-Record trial involving
5292 men and women aged ‡ 70 years who were mobile
before developing a low-trauma fracture, 1000 mg Ca and
20mg vitamin D, either alone or in combination, was not
found to significantly reduce the incidence of new low-
trauma fractures after 2 years(76). It is important to note,
however, that compliance was again low in this study
(possibly as low as 45% when non-responders to the
questionnaire were included) and only a small number of
subjects were measured for vitamin D status(77).
The 2005 Cochrane review has reported a reduced risk
for hip fracture (relative risk 0.81 (95% CI 0.68, 0.96) for
seven trials) and non-vertebral fractures (relative risk 0.87
(95% CI 0.78, 0.97) for seven trials) but no significant
effect on vertebral fractures(78). The authors conclude that
the effect may be restricted to those living in institutional
care. The most recent meta-analysis of the effect of Ca and
vitamin D supplements on fracture prevention suggests an
overall positive effect(79).
Vitamin K nutrition and bone
Vitamin K (‘koagulation vitamin’) was first described as
a dietary-derived coagulation factor(80); it was noted that a
bleeding disorder in chickens was corrected by feeding a
variety of vitamin K-rich diets. The fat-soluble vitamin
was finally isolated in 1939(81). Vitamin K refers to a
family of compounds with a common chemical structure,
2-methyl-1,4 napthoquinone, as shown in Fig. 10. Phyllo-
quinone (vitamin K1) is present in foods of plant origin.
Bacterial forms of vitamin K, referred to as the mena-
quinones (vitamin K2) differ in structure from phyllo-
quinone(82).
Vitamin K has an important function for the skeleton as
it acts as a cofactor in the post-translational carboxylation
of several bone proteins, with osteocalcin being the most
abundant(83). Deficiency of vitamin K results in the syn-
thesis of under-carboxylated osteocalcin(84). There are data
to show that low serum concentrations of either phyllo-
quinone or under-carboxylated osteocalcin are associated
with low BMD and increased risk for osteoporotic frac-
ture(85).
A number of recently published studies suggest a key
role for vitamin K nutrition for optimisation of bone
health(86). Phylloquinone supplementation (at a dose of
200mg/d, which would be obtainable in the diet from a
50 g portion of green leafy vegetables) in combination with
Ca (1000 mg) and vitamin D (10mg) was investigated over a
2-year period in a randomised placebo-controlled study (87).
Subjects who took the combined phylloquinone and
Phylloquinone (K1)
Plant derived    
Lipid soluble    
Bacterially derived
Lipid soluble
Synthetic
Water soluble
isoprenyl group
phytyl group
CH2-CH=C-CH2[-CH2-CH2-CH-CH2]3
Menaquinones (K2)
Menadione (K3)
CH3
[CH2-CH=C-CH2]
CH3
n 1–14
CH3
CH3
CH3
O
O
O
O
O
O
CH2
Fig. 10. Different forms of vitamin K. Vitamin K exists in two forms,
phylloquinone and menaquinones.
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Fig. 9. Cumulative probability of hip fracture (a) and other non-vertebral fractures
(b) in a placebo group (K) compared with a group treated with a calcium (1.2 g/d;
*) and vitamin D (20mg/d) supplement. Hip fracture (P = 0.040) and non-vertebral
fractures (P = 0.015) were significantly reduced for the supplemented group com-
pared with the placebo. (From Chapuy et al.(68); reproduced with permission.)
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vitamin D plus Ca supplement were found to show a sig-
nificant increase in ultra-distal BMD and bone mineral
content. The effect of phylloquinone (at a higher dose of
1 mg/d) on BMD has been studied in 155 healthy post-
menopausal women aged 50–60 years of age over 36
months(88). The study examined the potential comple-
mentary effect on post-menopausal bone loss of phyllo-
quinone, vitamin D (8mg/d) and a mineral supplement
(including 150 mg Mg/d, 500 mg Ca/d and 10 mg Zn/d).
The results indicate a positive effect of the phylloquinone
supplement on bone loss at the femoral neck, leading to a
35% reduction in bone loss when compared with placebo
after a period of 36 months.
Menaquinone supplementation has also been shown to
effectively improve markers of bone health, although it is
important to note that the doses of menaquinones used
could not be achieved via the diet(89). A recent meta-
analysis examining the effect of menaquionone supple-
mentation on vertebral and hip fracture shows a convincing
effect of pharmacological doses of menaquinones on
fracture rate (Fig. 11(a and b))(90,91). The role of vitamin K
on prevention (and possibly treatment) of osteoporosis is
an exciting area that requires further research.
Concluding remarks
It is widely recognised that there are genetic, environ-
mental, lifestyle and dietary determinants of risk of osteo-
porotic fracture, as well as interactions between them.
Favours vitamin K Favours control
OR
0·05 0·1 0·2 0·5 1 2 5 10 20
Study
(a)
(b)
OR % Weight
Sasaki et al.(96) 0·35 2·9
Shiraki et al.(97) 0·39 54·4
Iwamoto et al.(98) 0·32 10·4
Ishida & Kawai(99) 0·47 32·3
Overall 0·40 100·0
 Favours vitamin K Favours control
0·05 0·1 0·2 0·5 1
OR
2 5 10 20
Study
Sato et al.(100) 0·36 6·4
Shiraki et al.(97) 0·26 9·7
Sato et al.(101) 0·19 27·1
Ishida & Kawai(99) 0·37 6·5
Sato et al.(102) 0·18 50·3
Overall 0·21 100·0
0·02, 6·00
0·20, 0·75
0·07, 1·46
0·20, 1·10
0·25, 0·65
95% CI
OR % Weight95% CI
0·02, 5·90
0·03, 2·55
0·05, 0·75
0·02, 5·90
0·07, 0·49
0·10, 0·43
Fig. 11. Meta-analysis of the effect of menaquinones on (a) vertebral fracture prevention and (b) hip
fracture prevention. (From Cockrayne et al.(90); reproduced with permission.)
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There is good evidence to show that the effects of nutrition
on the skeleton are powerful and wide-ranging. Given that
by the year 2030 one in four of the adult population will
be elderly, it is vital that special attention is given to
nutritional strategies for the optimisation of bone health
throughout the life cycle, including the role of diet
in reducing falls(92). Ca and vitamin D are clearly key
nutrients for optimal bone health. At all costs, suboptimal
intakes or status must be prevented and dietary vitamin D
fortification should be considered for vulnerable groups
such as older adults, post-menopausal women, adolescent
females and amenorrhoeic women. Ca and vitamin D have
been shown to be effective strategies for fracture preven-
tion in the elderly, particularly for those populations in
which vitamin D insufficiency is rife. Ca supplementation
alone does not appear to be effective in reducing frac-
ture(93). In recent years, evidence has emerged for a role
for vitamin K in bone health. Further data are urgently
required to enable a fuller understanding of the complex
interaction between dietary factors and bone health.
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